MARKETSPERPSLIVE20SOCIAL
RESEARCH
Cash
Browse
Live20
Portfolio
Search
Social
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

Browse
Live20
Portfolio
Search
Social
Product
Perpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatory
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

All markets
AI
Big Tech & Business
Education
Energy
Medicine
Physics & Math
Public Health
Space

Medicine

Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Oveporexton by Takeda (this year)

Yes
--
No
--
$0 vol1 market
Medicine

When will Intellia Therapeutics submit a BLA for Lonvo-z?

before December
--
before November
--
$0 vol6 markets
Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before December
--
before November
--
$0 vol6 markets
Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before December
--
before November
--
$0 vol6 markets
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Iberdomide by Celgene (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Eli Lilly

Will the FDA approve VERVE-102?

Before 2030
1.01x
Before 2031
1.01x
$0 vol6 markets
Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
--
No
1.01x
$19,002 vol1 market
Eli Lilly

Will the FDA approve retatrutide?

Before Jan 1, 2027
1.01x
Before Jul 1, 2027
1.01x
$0 vol5 markets
Medicine

Will the FDA approve camizestrant for advanced breast cancer?

Before Oct 1, 2026
1.01x
Before Jan 1, 2027
1.01x
$0 vol3 markets
Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before October 2027
1.01x
Before 2028
1.01x
$21 vol3 markets
Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Jan 1, 2027
1.01x
Before July 2027
1.01x
$0 vol5 markets
Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before November
--
Before 2027
--
$0 vol3 markets
Biotech

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes
1.01x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.02x
No
1.01x
$0 vol1 market
Biotech

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.02x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.02x
No
1.01x
$0 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.02x
No
1.01x
$0 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.02x
No
1.01x
$0 vol1 market